JP2014506231A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506231A5
JP2014506231A5 JP2013530249A JP2013530249A JP2014506231A5 JP 2014506231 A5 JP2014506231 A5 JP 2014506231A5 JP 2013530249 A JP2013530249 A JP 2013530249A JP 2013530249 A JP2013530249 A JP 2013530249A JP 2014506231 A5 JP2014506231 A5 JP 2014506231A5
Authority
JP
Japan
Prior art keywords
composition
cancer
protein
composition according
smad7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506231A (ja
JP6124791B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/052499 external-priority patent/WO2012040295A2/en
Publication of JP2014506231A publication Critical patent/JP2014506231A/ja
Publication of JP2014506231A5 publication Critical patent/JP2014506231A5/ja
Application granted granted Critical
Publication of JP6124791B2 publication Critical patent/JP6124791B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530249A 2010-09-22 2011-09-21 Ｓｍａｄ７の治療的適用 Expired - Fee Related JP6124791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38544510P 2010-09-22 2010-09-22
US61/385,445 2010-09-22
PCT/US2011/052499 WO2012040295A2 (en) 2010-09-22 2011-09-21 Therapeutic applications of smad7

Publications (3)

Publication Number Publication Date
JP2014506231A JP2014506231A (ja) 2014-03-13
JP2014506231A5 true JP2014506231A5 (enExample) 2014-11-13
JP6124791B2 JP6124791B2 (ja) 2017-05-10

Family

ID=45874343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530249A Expired - Fee Related JP6124791B2 (ja) 2010-09-22 2011-09-21 Ｓｍａｄ７の治療的適用

Country Status (7)

Country Link
US (3) US9084746B2 (enExample)
EP (2) EP2618829B1 (enExample)
JP (1) JP6124791B2 (enExample)
CN (2) CN103501803B (enExample)
CA (1) CA2849382C (enExample)
IL (1) IL225406B (enExample)
WO (1) WO2012040295A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6124791B2 (ja) 2010-09-22 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Ｓｍａｄ７の治療的適用
US9422352B2 (en) 2013-03-08 2016-08-23 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics
US11268107B2 (en) 2015-04-23 2022-03-08 Washington State University SMAD7 gene delivery into muscle cells
KR101853923B1 (ko) * 2016-01-25 2018-05-02 연세대학교 산학협력단 Smad 단백질을 포함하는 자가 면역 질환 치료용 조성물, Smad 단백질을 포함하는 융합 단백질, 이를 제조하기 위한 벡터, 및 이의 제조 방법
US10772813B2 (en) 2016-06-03 2020-09-15 Colradel, LLC Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
US20200332302A1 (en) * 2017-12-30 2020-10-22 The Regents Of The University Of Colorado, A Body Corporate Therapeutics of ptd-smad7 fusion proteins
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification
AU2020376859A1 (en) * 2019-10-29 2022-05-26 The Trustees Of The University Of Pennsylvania Automated and precise device for dental plaque detection, monitoring and removal

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
ES2091916T3 (es) * 1989-12-21 1996-11-16 Whitehead Biomedical Inst Metodo para suministrar moleculas en el interior de celulas eucarioticas.
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
AU670316B2 (en) 1992-07-27 1996-07-11 Pioneer Hi-Bred International, Inc. An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
EP0903408A3 (en) * 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5436222A (en) 1993-03-15 1995-07-25 The Research Foundation Of State University Of New York Use of platelet factor 4 to treat inflammatory diseases
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
GB2320431B (en) 1996-12-20 2000-08-30 Johnson & Johnson Medical Compositions for the treatment of chronic wounds
US6251628B1 (en) 1997-05-20 2001-06-26 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding Smad7
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
IL138692A0 (en) 1998-03-27 2001-10-31 Lilly Co Eli Treatment and prevention of vascular disease
US8466134B1 (en) 1998-06-26 2013-06-18 Athena Neurosciences, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6998240B2 (en) * 2001-06-11 2006-02-14 Wisconsin Alumni Research Foundation Screen for selective inhibitors or activators of Smad protein function
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
WO2004022142A1 (en) 2002-09-06 2004-03-18 3M Innovative Properties Company Metering valve for a metered dose inhaler providing consistent delivery
KR100472938B1 (ko) * 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
CA2542276A1 (en) 2003-10-16 2005-04-28 The University Court Of The University Of Edinburgh Control of es cell self-renewal and lineage specification, and medium therefor
PL1845942T3 (pl) 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
MX2007012344A (es) 2005-04-05 2007-12-13 Pioneer Hi Bred Int Metodos y composiciones para disenar moleculas de acido nucleico para la expresion de polipeptido en plantas usando la desviacion de codon de virus de planta.
JP5505760B2 (ja) 2005-09-27 2014-05-28 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
WO2008105925A2 (en) 2006-09-01 2008-09-04 Oregon Health & Science University COMPOUNDS AND METHODS FOR MODULATING β-CATENIN/SMAD-7 INTERACTIONS
US20080114287A1 (en) * 2006-11-14 2008-05-15 Kar Neng Lai Ultrasound Microbubble Mediated Genes Delivery System
JP5951254B2 (ja) * 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
US8591961B2 (en) * 2008-09-04 2013-11-26 Allergan, Inc. Aesthetic treatment of scars and aging skin
US20110152352A1 (en) * 2008-06-10 2011-06-23 Tufts University Smad proteins control drosha-mediated mirna maturation
US20100184033A1 (en) * 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
JP6124791B2 (ja) 2010-09-22 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Ｓｍａｄ７の治療的適用
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9422352B2 (en) 2013-03-08 2016-08-23 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics

Similar Documents

Publication Publication Date Title
Dragan et al. Polysaccharides constructed hydrogels as vehicles for proteins and peptides. A review
MX2025014988A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer
JP2013067645A5 (enExample)
JP2015505843A5 (enExample)
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
US20180057819A1 (en) Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids
JP2016517888A5 (enExample)
TWI855246B (zh) 使用腫瘤治療電場（tt電場）之組合治療
NZ707328A (en) Virus-containing formulation and use thereof
JP2017523776A5 (enExample)
EP3818991A3 (en) Compositions and methods for treating diseases
JP2013508415A5 (enExample)
Ramadhani et al. Anthocyanin, tartaric acid, ascorbic acid of roselle flower (Hibiscus sabdariffa L.) for immunomodulatory adjuvant therapy in oral manifestation coronavirus disease-19: An immunoinformatic approach
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
JP2018528259A5 (enExample)
Jin et al. MiR-136 controls neurocytes apoptosis by regulating Tissue Inhibitor of Metalloproteinases-3 in spinal cord ischemic injury
JP2021504404A5 (enExample)
JP2013511975A5 (enExample)
JP2016510596A5 (enExample)
WO2016122806A8 (en) Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
Jin et al. Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge
Fan et al. The feasibility of targeting macrophage for disease treatment: roles of CEBPD
Gu et al. The roles of circular RNAs in ischemic stroke through modulating neuroinflammation
AU2017240702B2 (en) A composition comprising PIC for treatment of cancer